Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Yanqing Li
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06936800CT.gov Pinaverium Bromide Preventing Post Extracorporeal Shock Wave Lithotripsy Pancreatitis and Painful (PBPEP) | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pancreatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pinaverium (this asset) | Yanqing Li | N/A | D · 30 |
| Marcaine | Johns Hopkins University | P3 | BB |
| Pancrelipase | Changhai Hospital | P4 | BB |
| Kenacort | Centre hospitalier de l'Université de Montréal (CHUM) | P3 | BB |
| Pregabalin | Asian Institute of Gastroenterology, India | P2/3 | B |
| Pioglitazone | University of Michigan | P2 | B |
| Namisol | Radboud University Medical Center | P2 | B |
| Lidocaine | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P2 | B |
| Diazepam | Radboud University Medical Center | P2 | B |
+13 more in the Chronic Pancreatitis cohort
Other indications for Pinaverium
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Irritable Bowel Syndrome | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pinaverium in Chronic Pancreatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pinaverium-chronic-pancreatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →